PubMed Del Prato, S., Kahn, S.E., Pavo, I., Weerakkody, G.J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A.G., Riesmeyer, J.S., Heine, R.J., Wiese, R.J., & SURPASS-4 Investigators
1 Department of Clinical and Biomedical Sciences, Exeter, UK, 2 University of Geneva, Geneva, Switzerland, 3 Level 3, Exeter University, Exeter, UK, 4 Benaroya Research Institute, Seattle, WA, USA, 5 University of Melbourne, Parkville, Australia, 6 The Hospital for Sick Children, Toronto, ON, Canada, 7 Yale University School of Medicine, New Haven, CT, USA, 8 Texas Childrens Hospital, Houston, TX, USA, 9 Indiana Diabetes Research Center, Indiana University, Indianapolis, IN, USA, 10 Miller School of Medicine, Miami, FL, USA, 11 Indiana University School of Medicine, Indianapolis, USA, 12 Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK
A cumulative proportional responders graph was constructed according to Farrar et al
Colonic diverticular disease Scattered Patches of dark erythematous mucosa
Only one involved human patients, and no large, randomised controlled trials in humans were identified [4]
GLP-1 receptor agonists are expected to remain the main class of anti-obesity drugs and dominate the space for at least the next several years, and several startups with GLP-1 assets have debuted over the past few years
